PRTC
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- PureTech reported positive topline Phase 1b data for LYT-200 in high-risk MDS and AML patientsApr 22, 2026
- Seaport Therapeutics reported positive proof-of-concept Phase 1 topline results for GlyphAgo in healthy volunteersApr 2, 2026
- PureTech received orphan drug designations from the FDA and European Commission for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosisFeb 20, 2026
- PureTech announces successful end-of-Phase 2 FDA meeting for Deupirfenidone (LYT-100) in idiopathic pulmonary fibrosisDec 8, 2025
- PureTech presents new data from Phase 2b open-label extension study of Deupirfenidone (LYT-100), further supporting strong and durable efficacy and potential as new standard of care in idiopathic pulmonary fibrosisSep 29, 2025